INO
Price
$1.17
Change
-$0.05 (-4.13%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
120.98M
39 days until earnings call
Intraday BUY SELL Signals
PCSA
Price
$1.62
Change
-$0.00 (-0.00%)
Updated
Oct 2, 04:55 PM (EDT)
Capitalization
5.14M
Intraday BUY SELL Signals
Interact to see
Advertisement

INO vs PCSA

INO vs PCSA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
INO vs. PCSA commentary
Oct 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a Hold and PCSA is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
INO vs PCSA: Fundamental Ratings
INO
PCSA
OUTLOOK RATING
1..100
8267
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5988
P/E GROWTH RATING
1..100
10057
SEASONALITY SCORE
1..100
49n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PCSA's Valuation (45) in the null industry is somewhat better than the same rating for INO (79) in the Medical Specialties industry. This means that PCSA’s stock grew somewhat faster than INO’s over the last 12 months.

PCSA's Profit vs Risk Rating (100) in the null industry is in the same range as INO (100) in the Medical Specialties industry. This means that PCSA’s stock grew similarly to INO’s over the last 12 months.

PCSA's SMR Rating (100) in the null industry is in the same range as INO (100) in the Medical Specialties industry. This means that PCSA’s stock grew similarly to INO’s over the last 12 months.

INO's Price Growth Rating (59) in the Medical Specialties industry is in the same range as PCSA (88) in the null industry. This means that INO’s stock grew similarly to PCSA’s over the last 12 months.

PCSA's P/E Growth Rating (57) in the null industry is somewhat better than the same rating for INO (100) in the Medical Specialties industry. This means that PCSA’s stock grew somewhat faster than INO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INOPCSA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
69%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 15 days ago
79%
Bullish Trend 15 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 03, 2026
Stock price -- (INO: $1.21 vs. PCSA: $1.62)
Brand notoriety: INO: Notable vs. PCSA: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INO: 41% vs. PCSA: 7%
Market capitalization -- INO: $120.98M vs. PCSA: $5.14M
INO [@Biotechnology] is valued at $120.98M. PCSA’s [@Biotechnology] market capitalization is $5.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INO’s FA Score shows that 0 FA rating(s) are green while PCSA’s FA Score has 0 green FA rating(s).

  • INO’s FA Score: 0 green, 5 red.
  • PCSA’s FA Score: 0 green, 5 red.
According to our system of comparison, PCSA is a better buy in the long-term than INO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INO’s TA Score shows that 5 TA indicator(s) are bullish while PCSA’s TA Score has 3 bullish TA indicator(s).

  • INO’s TA Score: 5 bullish, 3 bearish.
  • PCSA’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, INO is a better buy in the short-term than PCSA.

Price Growth

INO (@Biotechnology) experienced а 0.00% price change this week, while PCSA (@Biotechnology) price change was -10.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

INO is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
INO
Daily Signal:
Gain/Loss:
PCSA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SCHL35.850.69
+1.96%
Scholastic Corp
CMS63.640.56
+0.89%
CMS Energy Corp
CBZ54.710.02
+0.04%
CBIZ
CHNR3.88-0.10
-2.51%
China Natural Resources Inc
MNOV1.63-0.04
-2.69%
Medicinova

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
-0.82%
AXON - INO
53%
Loosely correlated
-0.07%
ARRY - INO
52%
Loosely correlated
-3.47%
ALNY - INO
43%
Loosely correlated
-6.31%
LPCN - INO
41%
Loosely correlated
-5.91%
AMRN - INO
39%
Loosely correlated
-2.15%
More

PCSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PCSA has been loosely correlated with RADX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PCSA jumps, then RADX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCSA
1D Price
Change %
PCSA100%
-1.22%
RADX - PCSA
47%
Loosely correlated
-8.64%
INO - PCSA
38%
Loosely correlated
-0.82%
ONCO - PCSA
35%
Loosely correlated
-4.88%
IBO - PCSA
32%
Poorly correlated
-3.04%
EDIT - PCSA
28%
Poorly correlated
-1.95%
More